Status:
UNKNOWN
The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients
Lead Sponsor:
Xijing Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
The protein tyrosine kinase-7 (PTK7) is overexpressed in various types of human cancers. As a specific imaging agent of PTK7, 68Ga-Sgc8 was investigated in this study to assess its safety, biodistribu...
Detailed Description
The protein tyrosine kinase-7 (PTK7), also known as colon carcinoma kinase-4 (CCK4), is a member of the receptor tyrosine kinase superfamily, which is evolutionarily conserved and contains seven immun...
Eligibility Criteria
Inclusion
- Must be able to provide a written informed consent
- Males and females, ≥18 years old；
- Newly diagnosed colorectal patients and lymph node metastasis is not clear. The tumor will be surgically removed and histological diagnosis will be available.
Exclusion
- Females planning to bear a child recently or with childbearing potential；
- Known severe allergy or hypersensitivity to IV radiographic contrast；
- Inability to lie still for the entire imaging time because of cough, pain, etc.
- Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
- Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2019
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03385148
Start Date
January 1 2017
End Date
December 30 2019
Last Update
December 28 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital Nuclear Medicine Department
Xi'an, Shaanxi, China, 710032
2
Xijing Hospital
Xi'an, Shaanxi, China, 710032